In conclusion, the intensity and distribution of binding of the tau ligand [18F]AV‐1451 in a patient with a MAPT 10 + 16C>T mutation supports the use of this ligand in clinical studies of dementia, including frontotemporal lobar degeneration and CBS. This evidence concerns the gene MAPT and dementia.